GNI Group Ltd. (TYO:2160)

Market Cap	186.29B
Revenue (ttm)	22.98B
Net Income (ttm)	-1.01B
Shares Out	50.21M
EPS (ttm)	-20.11
PE Ratio	n/a
Forward PE	18.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,016,300
Average Volume	3,429,950
Open	3,735.00
Previous Close	3,710.00
Day's Range	3,560.00 - 3,740.00
52-Week Range	1,469.00 - 4,410.00
Beta	1.40
RSI	54.62
Earnings Date	May 15, 2025

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in deve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 867
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2160

Financial Performance

In 2024, GNI Group's revenue was 23.61 billion, a decrease of -9.22% compared to the previous year's 26.01 billion. Earnings were 1.10 billion, a decrease of -86.43%.